GlassScriptPhysician profile
April Stevens
NPI 1891059895
$5,736.73
in general payments reported to CMS, 2019-2025
42 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,610 · 2022: $1,471 · 2023: $1,308 · 2024: $749 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $649.22 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $561.97 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $478.30 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $460.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $450.36 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $392.38 | 2022-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $302.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $206.64 | 2021-2023 | |
| Antares Pharma, INC. | $195.95 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $151.32 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $148.30 | 2021-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.54 | 2021-2025 | Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $119.14 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $112.35 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $102.22 | 2021-2025 | Airsupra, Breztri |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.